Equity Overview
Price & Market Data
Price: $0.69
Daily Change: -$0.0498 / 7.22%
Range: $0.636 - $0.695
Market Cap: $1,573,769
Volume: 2,469
Performance Metrics
1 Week: -5.13%
1 Month: -6.65%
3 Months: -24.59%
6 Months: -50.68%
1 Year: -77.50%
YTD: -59.79%
Company Details
Employees: 2
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is based in Houston, Texas.